NCT00714857

Population Pharmacokinetics of Dexmedetomidine in ICU Patients

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: University of Turku · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Dexmedetomidine is a new, highly selective and potent alpha2-adrenoreceptor agonist registered for sedation of patients in intensive care units. Although the pharmacokinetics of dexmedetomidine have been studied previously also in an ICU setting, there is no information on the pharmacokinetics of long-lasting (\>48 hours) dexmedetomidine infusions in humans. The aim of this study is to study the pharmacokinetics of long-lasting dexmedetomidine infusions in ICU patients using the population pharmacokinetics approach.

Conditions

• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.

Timeline

• Start date: 2007-10-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2008-07-14
• Last updated: 2014-01-03

Locations

1 site across 1 country: Finland